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ABSTRACT
Background: The DNA of rheumatoid arthritis synovial
fibroblasts (RASF) is globally hypomethylated; this
contributes to an aggressive behaviour. In an attempt
to remethylate these cells, we supplemented with
methyl donors. We investigated the possible
interference of microRNAs (miRs).
Material and methods: RASF were treated with
L-methionine or betaine. Transcripts of de novo
methyltransferases (DNMTs) and miRs were measured
by real-time PCR, and a transcription PCR array was
performed. Levels of homocysteine, matrix
metalloproteinase-1 (MMP-1) and global DNA
methylation were determined. Transfection with
lipofectamine was performed with specific pre-miRs
and anti-miRs, such as miR29 and let7f.
Results: L-methionine was more efficient to increase
DNA methylation than betaine. This was associated
with a reduced expression of DNMT3A mRNA in
betaine-treated RASF. Betaine increases the expression
of miR29 in RASF which targets DNMT3A, thereby
limiting the remethylation process. Nevertheless,
betaine inhibited the expression of multiple
transcription factors, decreased the release of MMP-1,
biosynthesis of homocysteine and cell migration.
Conclusion: Alterations in cellular miRs profiles, in
particular the upregulation of miR29, which targets
DNMT3A, may limit the efficiency of betaine if it is
used as DNA remethylating agent. However, L-
methionine also has similar impact on miR29
expression. On the other hand, betaine has multiple
other beneficial effects on the activated phenotype of
RASF; it is not excluded that the effect of betaine on
DNMT3A is, at least in part, indirect. Clinical trials with
betaine could be promising.
INTRODUCTION
The global DNA hypomethylation in rheuma-
toid arthritis synovial ﬁbroblasts (RASF) is
associated with an intrinsically activated and
aggressive phenotype.1 DNA methylation is
performed by maintenance methyltransferase
(DNMT1) and de novo methyltransferases
(DNMT3A and DNMT3B). These enzymes
catalyse a transmethylation reaction using
S-adenosyl methionine (SAM) (ﬁgure 1A).
L-methionine and betaine feed into the
methionine cycle as precursors of SAM and
provide their methyl group.2 3 Betaine is
involved in the remethylation of homocysteine
to synthesise L-methionine, a pathway cata-
lysed by betaine-homocysteine methyltransfer-
ase (BHMT).4 L-methionine and betaine
might represent strategies to reverse DNA
hypomethylation locally in rheumatoid arth-
ritis (RA) synovial tissue and systemically in
peripheral T lymphocytes of patients with
RA.5 However, in RASF, the polyamine recyc-
ling pathway excessively consumes SAM, due
to an increased expression of spermine/
spermidine N1-acetyltransferase (SSAT1),
thereby interfering with the DNA methylation
process.6 7 We show here that, in comparison
with L-methionine, the efﬁciency of betaine
Key messages
▸ Rheumatoid arthritis synovial fibroblasts (RASF)
showed global DNA hypomethylation. Treatment
with methyl donors could be limited by the
intrinsically activated recycling of polyamines
that compete for S-adenosyl methionine (SAM).
▸ We showed here that a microRNAs-dependent
mechanism selectively target DNA methylation
possibly limiting the remethylation process. On
the other hand, betaine showed multiple benefi-
cial effects unrelated to DNA methylation, for
example, inhibiting the expression of multiple
transcription factors.
▸ Large interindividual variations can be expected
in outcomes of treatments with methyl donors,
depending on the active mechanisms limiting
the remethylation process. Nevertheless, clinical
trials with betaine could be promising.
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to remethylate RASF is lower, and this might be due to
the induction of microRNAs (miRs) targeting the expres-
sion of DNMTs, for example, miR9,8 miR299 10 and
let7f.11 12 We explored how miRs may selectively target
mechanism of DNA methylation. On the other hand, we
also show that betaine induced several beneﬁcial changes
unrelated to DNA methylation.
MATERIALS AND METHODS
Cell cultures
RASF (n=6–9) and osteoarthritis synovial ﬁbroblasts
(OASF) (n=6) were obtained after joint replacement
(Schulthess Clinic, Zurich, Switzerland). Patients ful-
ﬁlled the diagnostic criteria for RA13 or osteoarthritis
(OA).14 The procedure was approved by the Ethics
Committee of the University Hospital Zurich, and
canton of Zurich, Switzerland. SW982 cells from synovial
sarcoma and HepG2 from hepatocellular carcinoma
were obtained from American Type Culture Collection
(ATCC)/Laboratory of the Government Chemist (LGC)
Standards GmbH. RASFs were treated with
L-methionine or betaine (0–50 mM, Sigma-Aldrich).
The medium was replaced once a week with the same
concentration of the methyl donors. After 2 weeks, cell
culture supernatants were collected and cells were
detached using Accutase (PAA Laboratory). OASF were
passaged and treated for 2 weeks with 5-azacytidine
(0.1 μM, Sigma-Aldrich), replaced in fresh medium
twice a week. Proliferation rates were measured using a
Casy (Innovatis) cell counter and the xCELLigence
system (ACEA Biosciences). The scratch/migration assay
was performed as previously described.15
Real-time PCR
RNA was isolated using ReliaPrep minicolumn kit (for
mRNA, Promega) or miRNeasy kit (for total RNA, Qiagen)
and stored at −20°C. Genomic DNA was isolated using the
QIAamp DNA kit (Qiagen). Qubit 2.0 Fluorometer
(Invitrogen) was used to quantify the amounts of nucleic
acids. Reverse transcription was performed using
SuperScript First-Strand Synthesis System (Invitrogen) or
MultiScribe Reverse Transcriptase (Life Technologies). The
following primers were used for quantitative real-time PCR:
DNMT1 fwd 5′-TAACAGAAAAGGAATGTGTGAAGG-3′, rev
5′-TATTTCTGTTTGCAGAAATTCGTCC-3′; DNMT3A fwd
5′-TATTGATGAGCGCACAAGAGAGC-3′, rev 5′-GGGTGT
TCCAGGGTAACATTGAG-3′; DNMT3B fwd 5′-TGGCGAT
GGCAAGTTCTCCGAG-3′, rev 5′-CAGTGCCACCAGTTTG
TCTGC-3′. A commercially available TaqMan MicroRNA
Assay (Life Technologies) was used to measure miRs (miR9,
miR29, miR203, let7f). PCR was conducted using Taq
PCRx DNA Polymerase and a 7900 HT Fast Real-time PCR
System (Life Technologies). Regarding miRs, PCR was per-
formed using no AmpErase UNG, and single tube TaqMan
microRNA assay (Life Technologies). HPRT1 was used as
an endogenous control for normalisation and for miRs
mean values of RNU6B and RNU48 endogenous controls
were used. In addition, Transcription Factors RT2 Proﬁler
PCR Array (Qiagen) was performed.
Enzyme linked immunosorbent assays
Global DNA methylation was quantiﬁed using the 5-mC
DNA ELISA kit (Zymo Research). SSAT1 levels in cell
homogenates were measured using a SAT1 ELISA kit
(MyBioSource). L-homocysteine was quantiﬁed using
Figure 1 (A) One-carbon cycle and polyamine metabolism regulate DNA methylation. (B) RASF showed decreased global DNA
methylation that is comparable to OASF on 5-azacytidine. Treatment of RASF with L-methionine restored DNA methylation;
betaine was less efficient (2 weeks, 20 mM). Statistics: Box-and-Whisker plots, Mann-Whitney U-test between OASF and RASF,
Wilcoxon signed rank test between OASF before and after treatment with 5-azacytidine, as well as RASF before and after
treatment with L-methionine, *confirmed by Kruskal-Wallis with Dunn’s post hoc tests (overall: p<0.01; *confirmed for control
OASF vs control RASF, as well as between control RASF and RASF treated with L-methionine, n=6). 5-AzaC, 5-azacytidine;
BET, betaine; BHMT, betaine-homocysteine methyltransferase; DNMT, de novo methyltransferase; MET, L-methionine; miRs,
microRNAs; OASF, osteoarthritis synovial fibroblasts; RASF, rheumatoid arthritis synovial fibroblasts; SAH, S-adenosyl
homocysteine; SAM, S-adenosyl methionine; SSAT, spermine/spermidine N1-acetyltransferase.
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the Axis Homocysteine Enzyme Immunoassay kit.
DuoSet ELISA Development kit (R&D systems) was used
to measure matrix metalloproteinase-1 (MMP-1).
SSAT1 enzymatic activity assay
The assay was derived from the method of Lin et al.16
Adherent cells were lysed using 500 µL Sigma CelLytic
M solution. The homogenate was added with 500 mL of
50 mM Tris-HCl, 1 mM EDTA, pH 7.5 (all from
Sigma-Aldrich). It was adjusted to 100 µg/mL protein
using a bicinchoninic acid (BCA) protein assay (the
homogenate can be diluted using 25 mM tris-HCl and
0.5 mM EDTA, pH 7.5). This adjusted homogenate was
used for SSAT1 ELISA. The SSAT1 activity assay sample
mixture consisted of 196 µL sample and 4 µL 25 mM
acetyl-coenzyme A (end concentration 0.5 mM
(Sigma-Aldrich)). To 25 µL of spermine solution (of
different concentrations between 1 and 4 mM
(Sigma-Aldrich), prepared in 25 mM Tris-HCl and
0.5 mM EDTA, pH 7.5) 25 mL sample mixture was
added. To a ﬁnal volume of 100 mL 50 mL Ellman’s
reagent (2 mM DTNB, 1 mM EDTA, 50 mM Tris-HCl,
pH 7.5 (Sigma-Aldrich)) was added. The sample mix-
tures were then incubated for 5, 10, 15 or 20 min at 37°
C. After heating at 65°C for 5 min, the absorption was
measured at 450 nm. Bioactive human SSAT1 protein
puriﬁed from a HEK293T cells SSAT1 overexpression
lysate (OriGene) was used as standard.
Flow cytometry
Apoptosis was measured using Phycoerythrin Annexin V
Apoptosis Detection Kit I (BD Pharmingen). For com-
parison, apoptosis was induced in RASF within 24 hours
using 5 μM cycloheximide (Sigma-Aldrich). Intracellular
staining was performed using BD Perm2 solution
(Becton-Dickinson), as well as speciﬁc primary anti-
bodies: anti-BHMT and anti-SSAT1 or isotype control
antibodies (Abcam). The labelling was revealed using
ﬂuorescein-conjugated secondary antibodies ( Jackson
Laboratory).
Transfection
Transfection was conducted using Lipofectamine 2000
(Invitrogen), negative control Pre-miR, Pre-miR29,
Pre-miR-7f (50 nM) and negative control Anti-miR,
Anti-miR29 and Anti-miR-7f (100 nM) (Ambion Pre-miR
miRNA Precursors and Ambion Anti-miR miRNA
Inhibitors, respectively).
Statistics
Mann-Whitney U-test, Wilcoxon signed rank test,
Kruskal-Wallis with Dunn’s post hoc tests and
Spearman’s correlation were used to reveal the levels of
signiﬁcance and the preliminary relation among vari-
ables. Data are mainly presented as Box-and-Whisker
plots showing the median (horizontal line), 50% IQR
(Box, IQR) and up to 1.5 times IQR (Whiskers).
RESULTS
Methyl donors restores global DNA methylation in RASF
We measured cell proliferation and apoptosis with differ-
ent concentrations of L-methionine and betaine; 50 mM
betaine was cytostatic, but not apoptotic (see online
supplementary ﬁgure S1A–C). In RASF and SW982 cells,
which express BHMT, betaine was cytostatic, but not in
HepG2 cells, which lack functional BHMT (see online
supplementary ﬁgure S1D). In all the follow-up experi-
ments, we used concentrations of ≤20 mM, which are
neither cytostatic nor apoptotic. We conﬁrmed that
RASF showed decreased global DNA hypomethylation
that was comparable to OASF treated with a low non-
toxic dose of 5-azacytidine (ﬁgure 1B). Treatment of
RASF with L-methionine or betaine restored DNA
methylation; however, L-methionine was signiﬁcantly
more efﬁcient than betaine (ﬁgure 1B). L-methionine
and betaine restore DNA methylation, but not at the
same degree at a given molar concentration.
In RASF, considering that a baseline DNA methylation
of 3.5%, an increase to a ‘normal’ value of 4.2%, as it is
achieved with L-methionine, would corresponds to (95%
CI ) a 17.2% to 26.8% increase of methylation of the
whole DNA. For betaine, the 95% CI was 3.4% to 6.6%;
this would correspond to a Z-value of 10.4 and a highly
signiﬁcant difference between L-methionine and
betaine.
SSAT1 levels and DNA methylation on methyl donors
We were interested to identify the pathway which is
altered by methyl donors. Previously, we have shown that
the global DNA hypomethylation in RASF is associated
with higher expression of SSAT1, that is, an enhanced
recycling of polyamines. However, the increases in DNA
methylation on methyl donors were not signiﬁcantly asso-
ciated with changes in this pathway (see online
supplementary ﬁgure S2A,B). In order to validate the
ﬂow cytometric measurement, different methods to
assess SSAT1 levels and activity were compared (see
online supplementary ﬁgure S3A,B). As expected, the
three methods showed highly signiﬁcant correlations.
However, it is important to note that SSAT1 activity can
vary depending on the intracellular conditions. For
example (see online supplementary ﬁgure S3C), using a
colorimetric assay and a Lineweaver-Burk double recipro-
cal plot, we compared SSAT1 activity in protein extracts
from OASF and RASF (n=3 each). In RASF, Km was lower
(0.33 mM in RASF, compared with 0.52 mM in OASF)
and Vmax was either similar or lower (0.012–0.020 mM/
min in RASF, compared with 0.019 mM/min in OASF).
Thus, the activity of SSAT1 in RASF appeared limited by
competitive (in 1/3 RASF) and/or mixed intracellular
inhibitions (in 2/3 RASF), more than in OASF.
DNMT3A expression is more critical than SSAT1 on
betaine treatment
In comparison to untreated RASF, changes in DNMT
transcripts occurred after treatment with methyl donors
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(ﬁgure 2A,B); in cells treated with betaine, but not in
those treated with L-methionine, DNMT1 and DNMT3A
mRNAs were reduced by 35% and 40%, respectively. A
signiﬁcant association between increases in DNA methy-
lation and changes in DNMT3A expression was observed
on betaine, but not on L-methionine (ﬁgure 2C,D).
Interestingly, DNMT3B transcripts were increased on
L-methionine (ﬁgure 2A); however, no positive associ-
ation between changes in DNA methylation and
DNMT3B transcripts was found (data not shown). In
contrast, DNMT1 transcripts showed no change on
L-methionine and also no positive association with
changes in DNA methylation.
Increased miR29 expression might limit DNA
remethylation in RASF
We measured the levels of miRs described to have
DNMTs as targets (ie, miR9, miR29 and let7f), as well as
miR203 with promoter hypomethylated in RASF. Indeed,
we found that the level of some of these miRs changed
on L-methionine (ﬁgure 3A–D), also according to the
95% CI. Thus, L-methionine increased the levels of
miR29 (95% CI 1.14-fold to 1.66-fold change, n=9),
miR203 (1.34 to 1.86), miR9 (1.54 to 5.46) and let7f
(1.67 to 2.33). Changes in DNA methylation on methyl
donors inversely correlated with increases in miR29
expression (ﬁgure 3E), but not with the other miRs
Figure 2 (A and B) Changes in the levels of DNA methyltransferases (DNMTs) transcripts on treatment of RASF for 2 weeks
with 20 mM L-methionine (A) or betaine (B). The L-methionine-treated cells showed a trend towards more DNMT3B mRNA. At
opposite, on betaine (but not L-methionine), expressions of DNMT1 and DNMT3A mRNAs were reduced by 35% and 40%. (C
and D) A significant association between increases in DNA methylation and changes in DNMT3A transcripts expression was
observed after betaine (D), but not after L-methionine-treated treatment (C). Statistics: (A and B) Box-and-Whisker plots,
Wilcoxon signed rank test between RASF before and after treatment with L-methionine or betaine, *confirmed by Kruskal-Wallis
with Dunn’s post hoc tests (overall: p<0.05 for A. and p<0.001 for (B), *separately confirmed in (B) regarding DNMT1 and
DNMT3A, n=9); (C and D) linear regression lines with 95% CI, Spearman’s rank correlation coefficients. DNMT, de novo
methyltransferase; RASF, rheumatoid arthritis synovial fibroblasts.
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tested. The regression curves obtained on L-methionine
or betaine have similar slopes, but the change in DNA
methylation was lower in cells treated with betaine.
mir29 targets DNMT3A in synovial fibroblasts
We conﬁrmed that DNMT3A is a direct target of miR29.
Pre-miR29 or pre-let7f did not affect the expression of
DNMT1 transcripts (ﬁgure 4A,B). However, pre-miR29
—but not pre-let7f—reduced DNMT3A transcripts by
70% (ﬁgure 4C,D). The relationship between miR29
and DNMT3A transcripts was also shown using anti-miRs
(ﬁgure 4A,D); the difference between pre-miR29 and
anti-miR29 was highly signiﬁcant and conﬁrmed by the
post hoc corrected analysis of variance. Finally, we tested
the hypothesis that anti-miR29 restores the level of
DNMT3A mRNA in the presence of methyl donors
(ﬁgure 5A,B). Indeed, we observed a 138+43% increase
of DNMT3A on anti-miR29 transfection on betaine. The
differences between betaine alone and betaine plus
anti-miR29 for DNMT1 and DNMT3A transcripts were
signiﬁcant and conﬁrmed by the post hoc corrected ana-
lysis of variance.
Effects of betaine on other cellular processes
Apparently, betaine was less efﬁcient in remethylating RASF
in comparison to L-methionine due to downregulation of
Figure 3 Changes in microRNA expression on treatment of RASF for 2 weeks with 20 mM L-methionine or betaine. (A and B)
let7f and miR9 increased significantly in L-methionine-treated cells. (C and D) miR29 and miR203 increased after both
treatments, but only miR29 on L-methionine reached the level of significance after analysis of variance. (E and F) Changes in
DNA methylation on L-methionine (E) or betaine (F) inversely correlated with increases in miR29 expression. This relationship is
observed in spite that L-methionine and betaine have different efficiencies to increase DNA methylation in RASF. Statistics:
(A–D). Box-and-Whisker plots, Wilcoxon signed rank test between RASF before and after treatment with L-methionine or betaine,
*confirmed by Kruskal-Wallis with Dunn’s post hoc tests (overall: p<0.005 for (A—C), p=0.061 for (D); * separately confirmed in
(A–C) regarding let7f, miR9 and miR29 on L-methionine); (E and F) linear regression lines with 95% CI, Spearman’s rank
correlation coefficients. BET, betaine; MET, L-methionine; miRs, microRNAs; RASF, rheumatoid arthritis synovial fibroblasts.
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DNMT3A by miR29. This is suggested by the observed
associations above. On the other hand, betaine has
several beneﬁcial effects. Betaine doesn’t increase the
level of homocysteine (see online supplementary ﬁgure
S3) and downregulates the expression of multiple tran-
scription factors (ﬁgure 6A see online). The c-Jun tran-
scription factor was downregulated by both methyl
supplements (ﬁgure 6B). Thus, betaine showed multiple
beneﬁcial effects unrelated to the DNA remethylation
process, which at the end resulted in a modiﬁed behav-
iour of synovial ﬁbroblasts, for example, decreased
release of MMP-1 protein (ﬁgure 6C) and reduced cell
migration (ﬁgure 6D).
DISCUSSION
Previously, we showed that an intrinsically enhanced
polyamine recycling pathway, controlled by SSAT1, could
be responsible for an increased consumption of SAM
causing, at long term, the observed DNA hypomethyla-
tion in RASF.6 7 DNA remethylation of RASF using
methyl donors could not be possible in half of the cases
without concomitantly inhibiting this pathway.7 However,
in some other cases, treatment of RASF with a methyl
donor alone was already beneﬁcial, as shown in the
SCID mouse model of RA.7 In the current study, we
found that miR29 targets DNMT3A and limits DNA
remethylation on betaine. Increased SSAT1 levels didn’t
appear to be responsible for this limitation; however,
SSAT1 activity is dependent on the intracellular condi-
tions which can be different in RASF and OASF, as well
as before and after treatment with methyl donors; this
has to be further investigated. The intracellular competi-
tive/mixed inhibition of SSAT1 activity in RASF could
be due to negative feedback product inhibition (ie,
increased putrescine and/or diacetylpolyamines). Here,
we explored how miRs may selectively target DNA
methylation control. Thus, the remethylation efﬁciency
might be limited through upregulation of speciﬁc miRs
targeting epigenetic effectors.8–12 17
In RASF treated with L-methionine, DNMT3B tran-
scripts increased; this could explain at least in part the
remethylation. However, the correlation analysis doesn’t
show a positive relationship. This might be due to a shift
in the time course and has to be investigated in more
details. Interestingly, in betaine-treated cells, a positive
Figure 4 (A and B) Pre-miR29/anti-miR29 and pre-let7f/anti-let7f did not affect the expression of DNMT1 transcripts. (C and D)
Pre-miR29 decreased DNMT3A mRNA, while anti-miR29 increased it, suggesting that DNMT3A transcripts are direct targets of
miR29 in RASF (C); the difference between pre- and anti-miR29 was considered as significant after analysis of variance. For
comparison (D), pre-let7f/anti-let7f had much less effects on DNMT3A mRNA. Statistics: Box-and-Whisker plots, Wilcoxon signed
rank test between RASF before and after transfection with pre-miR and anti-miR, *confirmed by Kruskal-Wallis with Dunn’s post
hoc tests (overall: p=0.28 for (A), p=0.11 for (B), p<0.005 for (C), p=0.25 for (D); * confirmed separately for DNMT3A on
pre-miR29 and anti-miR29, n=6). DNMT, de novo methyltransferase; miRs, microRNAs; RASF, rheumatoid arthritis synovial
fibroblasts.
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Figure 5 Effects of anti-miR29 on the expression of (A) DNMT1 and (B) DNMT3A transcripts in untreated RASF (control) or
treated with L-methionine or betaine. Betaine reduced the expression of DNMT1 and DNMT3A. This can be normalised by
treatment with anti-miR29; the significant increase between betaine alone and betaine plus anti-miR29 is confirmed by the
analysis of variance. Statistics: Box-and-Whisker plots, Wilcoxon signed rank test between RASF before and after transfection
with anti-miR29, *confirmed by Kruskal-Wallis with Dunn’s post hoc tests (overall: p<0.005 for (A and B); *confirmed separately
for BET vs BET+anti-miR29 regarding DNMT1 and DNMT3A, n=6). BET, betaine; DNMT, de novo methyltransferase; MET,
L-methionine; miRs, microRNAs; RASF, rheumatoid arthritis synovial fibroblasts.
Figure 6 (A) The mRNA expression of multiple transcription factors was reduced in betaine-treated RASF, as shown by a
transcription factor array; in comparison, L-methionine only reduced c-Jun transcripts. (B) Decreased c-Jun transcript confirmed
by real-time PCR. (C) Reduced MMP-1 released by cells treated with L-methionine or betaine. (D) Inhibition of cell migration on a
low non-cytostatic dose of betaine. Statistics: bars, Box-and-Whisker plots, Wilcoxon signed rank tests. BET, betaine; MET,
L-methionine; MMP-1, matrix metalloproteinase-1; RASF, rheumatoid arthritis synovial fibroblasts.
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relationship between changes in DNA methylation and
DNMT3A transcripts was observed. It might be argued
that the change in DNA methylation is low. In RASF,
considering that the baseline DNA methylation is about
3.5%, an increase to a ‘normal’ value of 4.2%, as it is
achieved with L-methionine, would correspond to a 17–
27% increase of methylation of the whole DNA. This is
probably the maximum that can be achieved and may
primarily concern the remethylation of repetitive
sequences.
The levels of DNMTs are often increased in various
tumours, possibly playing a role in the hypermethylation
of promoter CpG-rich regions of tumour suppressor
genes.18 DNMT3A and DNMT3B play also an essential
role in early embryogenesis, the stage in which most pro-
grammed de novo methylation events occur. They
cannot differentiate between unmethylated and hemi-
methylated CpG sites. Therefore, in differentiated
somatic cells, the levels of de novo DNMTs have to be
tightly regulated.
In RASF, on betaine, the increase of miR29 correlated
with the decrease in DNMT3A transcripts. We validated
DNMT3A as a target for miR29 in synovial ﬁbroblasts.
The inverse relationship between miR29 and DNMT3A
was also described by others in ischaemic brain
damages.19 Moreover, miR29 has multiple regulatory
functions, for example regulating collagen expression in
systemic sclerosis20 and DNMT3A/3B expressions in
haematologic malignancies.21 However, miR29 is not
upregulated in RA under basal conditions, neither in
peripheral blood leucocytes compared with healthy
donors,22 nor in synovial ﬁbroblasts compared with OA
(data not shown). Nevertheless, under certain condi-
tions, our data suggested that miR29 selectively target
mechanisms of DNA methylation.
In spite of the associations reported here, the central
question of whether betaine was less efﬁcient than
L-methionine, due to downregulation of DNMT3A by
miR29, remains partially unanswered. L-methionine and
betaine showed similar effects on miR29 expression, the
important difference being that in betaine-treated cells
DNMT3A is restored to basal levels after transfection
with anti-miR29. The question remains how increased
miR29 in L-methionine-treated cells doesn’t reduce
DNMT3A and limit DNA methylation at the same
extent? Our results would imply that miR29 only control
DNMT3A levels in the presence of betaine. Considering
the many effects of betaine unrelated to DNA methyla-
tion, in particular on a variety of transcription factors, it
might be possible that the effect of betaine is indirect.
The idea to use L-methionine or SAM in the treat-
ment of RA is not novel. In an early clinical study,
L-methionine (5 or 10 g/day) was given to patients as a
treatment for RA.23 No statistical difference between
treatment and controls and no serious adverse effects
were reported. Even previously, a double-blinded multi-
centre study reported that the beneﬁcial effect of SAM
is slightly better than ibuprofen in the treatment of hip
and knee OA.24 Both drugs were given orally, 0.4 g
thrice daily for 30 days. Such observations raise the ques-
tion of dosage schedule and bioavailability, as well as
whether such treatments can reach in vivo the effective
and non-cytostatic of dose of 20 mM L-methionine used
in vitro. Compared with the free plasma level of
L-methionine (about 0.02 mM) or to the interstitial con-
centration (about 0.11 mM),25 it is 102 to 103 times
higher. The intracellular level will depend on the
L-methionine transmembrane transporter activity.
Higher doses will trigger the conversion into homocyst-
eine. Betaine plasma concentrations increased sharply
after oral dosing (50 mg/kg per os), reaching a peak
concentration of 0.9 mM after 90 min.26 The clearance
is fast, with a T1/2 of about 30 min. Thus, the concentra-
tion of 20 mM used in vitro can be considered as very
high; however, we already detected changes in cell
migration with 1 mM. The local concentrations,
however, are certainly higher if a betaine solution is dir-
ectly injected into the knee joint. Clearly, more informa-
tion regarding formulation, pharmacokinetic and
bioavailability is needed.
The induction of counter-regulatory miRs might rep-
resent a general mechanism avoiding an excessive DNA
methylation in presence of elevated intracellular betaine
levels. It can be hypothesised that repressing the levels
of miR29 in RASF during betaine supplementation by
using anti-miR29 might enhance the effects of betaine
on DNA remethylation.
Betaine inhibited the proliferation of synovial ﬁbro-
blasts and SW982 sarcoma cells, but not of HepG2 cells,
a hepatic tumour cell line that lost the ability to produce
BHMT.4 This showed that hepatocytes and synovial ﬁbro-
blasts express BHMT, allowing a folate-independent
methionine metabolism. Betaine, in contrast to
L-methionine, decreased homocysteine levels. In RA,
this could be beneﬁcial since elevated plasma homocyst-
eine has been associated with increased risk of cardiovas-
cular diseases.27
The c-Jun transcription is downregulated by
L-methionine and betaine. Thus, it can be expected that
L-methionine and betaine can reduce inﬂammation and
joint destruction in vivo, even independently of DNA
remethylation. Betaine downregulates, in addition,
mRNAs of multiple transcription factors, such as
HAND1, GATA1, ATF3; in particular, the effect on ATF3
transcription could explain betaine’s antimigrating and
cytostatic properties.28 Clinical trials with betaine could
be promising.
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